Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

7.16
+0.19002.73%
Post-market: 7.160.00000.00%16:10 EDT
Volume:1.37M
Turnover:9.75M
Market Cap:923.64M
PE:-1.88
High:7.29
Open:7.04
Low:6.90
Close:6.97
52wk High:31.35
52wk Low:4.28
Shares:129.00M
Float Shares:97.15M
Volume Ratio:0.52
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8005
EPS(LYR):-2.8616
ROE:-93.65%
ROA:-45.34%
PB:2.04
PE(LYR):-2.50

Loading ...

Alumis price target lowered to $29 from $39 at Morgan Stanley

TIPRANKS
·
Sep 02

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)

TIPRANKS
·
Sep 02

HC Wainwright Upgrades Alumis to Buy From Neutral, Adjusts Price Target to $15 From $25

MT Newswires Live
·
Sep 02

Alumis upgraded to Buy from Neutral at H.C. Wainwright

TIPRANKS
·
Sep 02

Alumis Inc. : H.c. Wainwright Cuts to Buy from Neutral

THOMSON REUTERS
·
Sep 02

U.S. Research Roundup-Adobe, Dell Technologies, Zscaler

Reuters
·
Sep 02

Alumis Inc. : Leerink Partners Cuts Target Price to $26 from $34

THOMSON REUTERS
·
Sep 02

Small U.S. Stocks Decrease; Alumis Takes Biggest Hit

Dow Jones
·
Sep 02

Alumis price target lowered to $27 from $35 at Baird

TIPRANKS
·
Sep 02

Top Midday Decliners

MT Newswires Live
·
Sep 02

Alumis price target lowered to $25 from $51 at Wells Fargo

TIPRANKS
·
Sep 02

Alumis falls -58.9%

TIPRANKS
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

Alumis Down over 54%, on Pace for Record Percent Decrease

Dow Jones
·
Sep 01

Alumis Set for Worst Day After Lupus Drug Misses Main Goal in Mid-Stage Trial

Reuters
·
Sep 01

Alumis Eyes Late-Stage Lupus Study Despite Trial Miss

Reuters
·
Sep 01

Alumis Reports Phase 2b Envudeucitinib Data in Lupus

TIPRANKS
·
Sep 01

Alumis' Lupus Drug Fails Mid-Stage Trial Goal

Reuters
·
Sep 01

Alumis Says Phase 2b LUMUS Trial of Envudeucitinib in Systemic Lupus Erythematosus Misses Primary Endpoint

Reuters
·
Sep 01

Alumis - Envudeucitinib Well Tolerated with no New Safety Signals in Lumus Trial

THOMSON REUTERS
·
Sep 01